Equibles does not estimate personal net worth.
Get an email with a short summary when Dyne Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get DYN alertsRon Bastra has spoken on 2 investor events across 1 company, most recently for Dyne Therapeutics, Inc. on June 3, 2026. Dyne Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Dyne Therapeutics, Inc. includes John Cox (CEO and Board Member), John G. Cox (CEO and Board Member), Josh Brumm (CEO) and 5 others.
“I think it's going to be a mix of the three populations, ones that are currently on treatment, ones that have discontinued treatment, ones that have never been treated.”
“It speaks to the execution that the team is doing, right? We're on track, as you said, and Q2 will initiate the trial. And as you said, you know, 90 patients, one-to-one randomized, 72 weeks rise from floor velocity as the primary endpoint.”
Transcript header (unverified)
Biotechnology · Healthcare
